PE20090416A1 - ANTICUERPOS CONTRA C3b Y METODOS PARA LA PREVENCION Y EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON EL COMPLEMENTO - Google Patents

ANTICUERPOS CONTRA C3b Y METODOS PARA LA PREVENCION Y EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON EL COMPLEMENTO

Info

Publication number
PE20090416A1
PE20090416A1 PE2008000973A PE2008000973A PE20090416A1 PE 20090416 A1 PE20090416 A1 PE 20090416A1 PE 2008000973 A PE2008000973 A PE 2008000973A PE 2008000973 A PE2008000973 A PE 2008000973A PE 20090416 A1 PE20090416 A1 PE 20090416A1
Authority
PE
Peru
Prior art keywords
antibody
treatment
complement
antibodies
prevention
Prior art date
Application number
PE2008000973A
Other languages
English (en)
Inventor
Menno Van Lookeren Campagne
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39712089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20090416(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of PE20090416A1 publication Critical patent/PE20090416A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)

Abstract

SE REFIERE A UN ANTICUERPO O FRAGMENTO DE ANTICUERPO HUMANIZADO ANTI-C3b QUE ES UN INHIBIDOR SELECTIVO DE LA VIA ALTERNATIVA DEL COMPLEMENTO QUE ACTUA INHIBIENDO EL ENLACE DE C5 CON C3b Y COMPRENDE: A) SECUENCIAS CDR DE CADENA PESADA DE SEC ID N‘ 1 A 4 DEL ANTICUERPO S77; Y B) SECUENCIAS CDR DE CADENA LIVIANA DE SEC ID N‘ 5 A 8 DEL ANTICUERPO S77. DICHO FRAGMENTO DE ANTICUERPO ES Fab, Fab', scFv, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA QUE CONTIENE DICHO ANTICUERPO SIENDO UTIL EN EL TRATAMIENTO DE ARTRITIS REUMATOIDEA, PENFIGO, GLOMERULONEFRITIS, VASCULITIS, INSUFICIENCIA RENAL AGUDA
PE2008000973A 2007-06-07 2008-06-06 ANTICUERPOS CONTRA C3b Y METODOS PARA LA PREVENCION Y EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON EL COMPLEMENTO PE20090416A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93372107P 2007-06-07 2007-06-07
US5506808P 2008-05-21 2008-05-21

Publications (1)

Publication Number Publication Date
PE20090416A1 true PE20090416A1 (es) 2009-04-18

Family

ID=39712089

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000973A PE20090416A1 (es) 2007-06-07 2008-06-06 ANTICUERPOS CONTRA C3b Y METODOS PARA LA PREVENCION Y EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON EL COMPLEMENTO

Country Status (18)

Country Link
US (2) US8012473B2 (es)
EP (1) EP2162470A2 (es)
JP (3) JP5683265B2 (es)
KR (3) KR20170023212A (es)
CN (1) CN101809034B (es)
AR (1) AR066916A1 (es)
AU (1) AU2008262048B2 (es)
BR (1) BRPI0812767A2 (es)
CA (1) CA2690124A1 (es)
CL (1) CL2008001656A1 (es)
IL (1) IL201820A0 (es)
MX (1) MX2009013082A (es)
PE (1) PE20090416A1 (es)
RU (1) RU2473563C2 (es)
SG (2) SG182165A1 (es)
TW (2) TWI441832B (es)
WO (1) WO2008154251A2 (es)
ZA (1) ZA200907575B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2656063C (en) 2006-06-21 2016-10-18 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
CL2008003241A1 (es) * 2007-11-02 2009-07-31 Novartis Ag Molecula de enlace que comprende una porcion de enlace de antigeno que se enlaza con un neoepitopo de c3b; composicion farmaceutica que la comprende; y su uso para tratar trastornos oculares
US20100291106A1 (en) * 2009-05-06 2010-11-18 Novartis Ag Compositions and methods for antibodies targeting complement protein c3b
AU2010266127B2 (en) 2009-07-02 2015-11-05 Musc Foundation For Research Development Methods of stimulating liver regeneration
EP2496259B1 (en) 2009-11-05 2017-02-22 Alexion Pharmaceuticals, Inc. Treatment of paroxysmal nocturnal hemoglobinuria
WO2011084496A1 (en) * 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
AU2011233753A1 (en) * 2010-03-31 2012-09-13 Anamar Ab Method to detect tissue degradation leading to inflammation
US9650447B2 (en) 2010-05-14 2017-05-16 The Regents Of The University Of Colorado, A Body Corporate Complement receptor 2 (CR2) targeting groups
EA201291328A1 (ru) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3
WO2012075023A2 (en) * 2010-11-29 2012-06-07 Novelmed Therapeutics, Inc. Neoantibodies for diagnosing tissue injury
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
EP2841453B1 (en) * 2012-04-03 2019-11-27 NovelMed Therapeutics, Inc. Humanized and chimeric anti-factor c3 antibodies and uses thereof
US10413620B2 (en) 2012-08-17 2019-09-17 The Regents Of The University Of Colorado, A Body Corporate Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
WO2014028865A1 (en) 2012-08-17 2014-02-20 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for detecting complement activation
JP6563815B2 (ja) * 2013-01-23 2019-08-21 エムユーエスシー ファウンデーション フォー リサーチ ディベロップメント 天然抗体に由来する構築物を標的化すること及びその使用
EP3290922A1 (en) 2013-08-07 2018-03-07 Alexion Pharmaceuticals, Inc. Atypical hemolytic uremic syndrome (ahus) biomarker proteins
CA2934462A1 (en) * 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
HUE050921T2 (hu) * 2014-02-26 2021-01-28 Allergan Inc C5 komplementkomponens antitestek
CA2939586A1 (en) 2014-02-27 2015-09-03 Allergan, Inc. Complement factor bb antibodies
ES2750556T3 (es) 2014-06-12 2020-03-26 Ra Pharmaceuticals Inc Modulación de actividad del complemento
EP3183266B1 (en) * 2014-08-20 2019-05-29 Stichting Sanquin Bloedvoorziening Factor h potentiating antibodies and uses thereof
US9937222B2 (en) 2015-01-28 2018-04-10 Ra Pharmaceuticals, Inc. Modulators of complement activity
RU2584582C1 (ru) * 2015-03-16 2016-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело сс3-4 к конформационному эпитопу с3 человека, штамм гибридной днк мыши рккк(п)764д - продуцент моноклонального антитела сс3-4
PT3685847T (pt) 2015-12-16 2023-03-14 Ra Pharmaceuticals Inc Moduladores de atividade de complemento
GB201608046D0 (en) * 2016-05-09 2016-06-22 Cambridge Entpr Ltd And Syndey Children S Hospitals Network Randwick And Westmead Incorporating The Treatment of complement-mediated disorders
RU2630647C1 (ru) * 2016-05-27 2017-09-11 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА
EP3526248A4 (en) 2016-10-17 2020-07-08 Musc Foundation for Research Development COMPOSITIONS AND METHODS FOR TREATING LESIONS OF THE CENTRAL VENEER SYSTEM
EP3551210A1 (en) 2016-12-07 2019-10-16 RA Pharmaceuticals, Inc. Modulators of complement activity
CA3054167A1 (en) * 2017-02-27 2018-08-30 Regeneron Pharmaceuticals, Inc. Humanized model of kidney and liver disorders
MX2020005547A (es) 2017-12-04 2020-08-20 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
GB201800620D0 (en) * 2018-01-15 2018-02-28 Univ Manchester C3b Binding Polypeptide
MX2020010323A (es) * 2018-04-03 2021-01-08 Ngm Biopharmaceuticals Inc Agentes de union al componente del complemento c3 (c3) y metodos para su uso.
RU2687609C1 (ru) * 2018-05-30 2019-05-15 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Гуманизированное антитело к конформационному эпитопу сз компонента комплемента человека
US12110321B2 (en) 2018-06-11 2024-10-08 Aarhus Universitet Single domain antibodies for complement regulation
GB2583560A (en) 2018-12-11 2020-11-04 Admirx Inc Fusion protein constructs for complement associated disease
CN113543796A (zh) 2019-03-08 2021-10-22 Ra制药公司 齐鲁考普作为深层组织穿透性c5抑制剂
US20230115176A1 (en) 2019-03-29 2023-04-13 Ra Pharmaceuticals, Inc. Complement Modulators and Related Methods
WO2020219822A1 (en) 2019-04-24 2020-10-29 Ra Pharmaceuticals, Inc. Compositions and methods for modulating complement activity
KR20220057530A (ko) 2019-07-17 2022-05-09 제미니 테라퓨틱스 서브, 인코포레이티드 인자 h 강화 항체 및 이의 용도
KR20230105972A (ko) 2022-01-05 2023-07-12 주식회사 카나프테라퓨틱스 혈관신생 억제제가 결합된 항-C3b 항체 또는 항-C5 항체 및 이의 용도
WO2023212298A1 (en) * 2022-04-29 2023-11-02 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
TW202417510A (zh) * 2022-09-20 2024-05-01 美商威特拉公司 用ｃ３ｂ抗體治療補體介導之疾病及病症

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4419446A (en) * 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4873191A (en) * 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
US4601978A (en) * 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) * 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) * 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) * 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) * 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4736866B1 (en) * 1984-06-22 1988-04-12 Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) * 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) * 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
ES2241710T3 (es) 1991-11-25 2005-11-01 Enzon, Inc. Procedimiento para producir proteinas multivalentes de union a antigeno.
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
AU6808194A (en) * 1993-05-31 1994-12-20 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
SK121798A3 (en) * 1996-03-07 1999-04-13 Imutran Ltd Native protein of a complement line, a fragment or variant of protein, dna sequence coding a protein, dna construct, a conjugate containing protein, pharmaceutical composition and use of protein
US8007798B2 (en) * 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) * 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
ES2488819T3 (es) * 1998-02-20 2014-08-29 Genentech, Inc. Inhibidores de la activación del complemento
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7959919B2 (en) * 2003-11-19 2011-06-14 Novelmed Therapeutics, Inc. Method of inhibiting factor B-mediated complement activation
WO2006012621A2 (en) * 2004-07-23 2006-02-02 University Of Virginia Patent Foundation Compositions and methods for regulating the alternative pathway of complement
AU2005313971B2 (en) * 2004-12-08 2011-10-13 Immunomedics, Inc. Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer
US8192742B2 (en) * 2007-03-23 2012-06-05 NovelMed Therapeutics Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof

Also Published As

Publication number Publication date
CA2690124A1 (en) 2008-12-18
RU2473563C2 (ru) 2013-01-27
AU2008262048A1 (en) 2008-12-18
TW201441255A (zh) 2014-11-01
US20090081211A1 (en) 2009-03-26
BRPI0812767A2 (pt) 2014-12-02
SG10201608952QA (en) 2016-12-29
JP5980249B2 (ja) 2016-08-31
WO2008154251A3 (en) 2009-05-14
EP2162470A2 (en) 2010-03-17
KR20150029002A (ko) 2015-03-17
SG182165A1 (en) 2012-07-30
AR066916A1 (es) 2009-09-23
KR20170023212A (ko) 2017-03-02
JP2014088434A (ja) 2014-05-15
AU2008262048B2 (en) 2013-09-26
CN101809034B (zh) 2015-07-08
ZA200907575B (en) 2011-02-23
US8012473B2 (en) 2011-09-06
JP2016204382A (ja) 2016-12-08
KR20100041743A (ko) 2010-04-22
CL2008001656A1 (es) 2009-05-22
TW200911827A (en) 2009-03-16
IL201820A0 (en) 2010-06-16
TWI557137B (zh) 2016-11-11
CN101809034A (zh) 2010-08-18
RU2009149385A (ru) 2011-07-20
US8377437B2 (en) 2013-02-19
KR101572700B1 (ko) 2015-11-30
MX2009013082A (es) 2010-01-15
WO2008154251A4 (en) 2009-07-09
JP5683265B2 (ja) 2015-03-11
TWI441832B (zh) 2014-06-21
WO2008154251A2 (en) 2008-12-18
JP2011504872A (ja) 2011-02-17
US20120128674A1 (en) 2012-05-24

Similar Documents

Publication Publication Date Title
PE20090416A1 (es) ANTICUERPOS CONTRA C3b Y METODOS PARA LA PREVENCION Y EL TRATAMIENTO DE TRASTORNOS ASOCIADOS CON EL COMPLEMENTO
PE20120899A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c3b
AR123876A2 (es) Composición farmacéutica de anticuerpos anti-cgrp
ES2533242T3 (es) Prevención y tratamiento de afecciones oculares asociadas con el complemento
PE20080846A1 (es) Composiciones y metodos relacionados con los anticuerpos receptores de glucagon
CO6430469A2 (es) Anticuerpos humanizados que se unen a cd19 y sus usos
AR096895A2 (es) Anticuerpo que se une a la citoquina, linfopoyetina estromal tímica (tslp)
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20140806A1 (es) Anticuerpos anti-factor d humanizados y sus usos
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
PE20120079A1 (es) Moleculas de anticuerpos mejoradas
PE20140814A1 (es) Anticuerpos contra la angiopoyetina 2 humana
PE20091674A1 (es) Antagonistas del receptor de glucagon
PE20091351A1 (es) Anticuerpos humanizados especificos para el factor von willebrand
PE20091196A1 (es) Anticuerpos contra el vegf completamente humano, composiciones y metodos
CO6260105A2 (es) Anticuerpos humanos contra cd20 humano y metodo para utilizarlos
PE20141271A1 (es) Anticuerpos tipo receptor de celulas t especificos para un peptido wt1 presentado por hla-a2
PE20081503A1 (es) Miembros de union para il-6
AR052959A1 (es) Anticuerpos anti- ccr5 y usos de los mismos
PE20140247A1 (es) Anticuerpos anti-cd38
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
PE20100251A1 (es) Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina
EA201290173A1 (ru) Антитела против эндоглина
PE20110382A1 (es) Tratamiento de enfermedad autoinmunitaria e inflamatoria
UA104587C2 (ru) Моноклональное антитело и способ его применения

Legal Events

Date Code Title Description
FC Refusal
FG Grant, registration
FD Application declared void or lapsed